London · Delayed Price · Currency is GBP · Price in GBX Venture Life Group Earnings Call Transcripts
Fiscal Year 2025
-
Major divestments and a shift to a brand-focused model drove 11% organic and 32% reported revenue growth, with strong cash generation and double-digit growth continuing into 2026. Power brands excelled, especially in women's and men's health, while digital transformation and innovation underpin future expansion.
-
Revenue grew 43% to £15.4m, with 12.5% organic growth and gross margin up to 43.1%. Strong cash position and divestment of non-core assets support a brand-focused, high-margin strategy, with continued investment in innovation, marketing, and M&A.
-
Divestment of CDMO operations and peripheral brands streamlines the business into a focused, high-margin consumer healthcare platform. Proceeds will fund core brand growth, innovation, and M&A, with enhanced digital capabilities and expansion in key markets.
Fiscal Year 2024
-
Year-end 2024 results show a strategic pivot to a capital-light, high-margin brand model, with strong growth in core segments and the Health & Her acquisition accelerating U.K. and U.S. expansion. Divestments provide cash for organic growth and M&A, with further margin gains expected.